Literature DB >> 16952359

Long-term suppression of reproductive function by a single dose of gonadotropin-releasing hormone antagonists in a sheep model.

Antonio Gonzalez-Bulnes1, Carlos J H Souza, Rex J Scaramuzzi, Bruce K Campbell, David T Baird.   

Abstract

OBJECTIVE: To determine the effect of single long-acting doses of GnRH antagonists on reproductive function in a sheep model.
DESIGN: Observational, model study.
SETTING: University-affiliated research unit. ANIMAL(S): Nine intact mature Merino sheep in experiment 1 and 12 mature Merino-crossed ewes with the ovary autotransplanted to the neck in experiment 2. INTERVENTION(S): Synchronization of estrous cycle either with intravaginal progestins or prostaglandin F2alpha analogues and treatment with a single dose of GnRH antagonist; evaluation of reproductive activity, plasma sampling, and ovarian ultrasonography. MAIN OUTCOME MEASURE(S): Determination of estrus behavior; plasma concentrations of P, FSH, LH, and inhibin A; and number and size of ovarian follicles. RESULT(S): In both experiments, the concentrations of FSH and LH were suppressed when compared with those in control ewes. In experiment 1, the ovulatory cycles were suppressed for > or = 55 days in treated sheep. In experiment 2, there were no follicles sized > or = 5 mm in treated ewes for 50 days. CONCLUSION(S): The suppression of the development of large follicles for > or = 30 days after a single injection of a long-acting GnRH antagonist provides a novel convenient method of pretreatment before COS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952359     DOI: 10.1016/j.fertnstert.2006.02.104

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

1.  A Proof-of-Concept Clinical Trial of A Single Luteal Use of Long-Acting Gonadotropin-Releasing Hormone Antagonist Degarelix in Controlled Ovarian Stimulation for In Vitro Fertilization: Long Antagonist Protocol.

Authors:  Evangelos G Papanikolaou; Hakan Yarali; Evi Timotheou; Michael Grynberg; Odysseas Zafeiratis; Herman Tournaye; Robert Najdecki
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-01       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.